- Lupin’s net income for the first quarter was 12.2 billion rupees, which is a 52% increase compared to the same period last year and surpassed the estimate of 10.9 billion rupees.
- The company’s revenue for the quarter stood at 62.7 billion rupees, showing a 12% year-on-year increase, although it was slightly below the estimated 63.37 billion rupees.
- Total costs for the quarter were 49.3 billion rupees, representing a 5.6% increase from the previous year.
- Lupin reported other income of 790.4 million rupees, which is a 17% rise compared to the prior year.
- Current market analysts’ recommendations include 23 buys, 13 holds, and 4 sells.
Lupin Ltd on Smartkarma
Analyst coverage of Lupin Ltd on Smartkarma reveals a positive outlook on the company’s performance. According to the research report by Tina Banerjee titled “Lupin Ltd (LPC IN): Differentiated Portfolio Drives Solid Q3FY25 Performance; Momentum to Continue,” Lupin reported a strong Q3FY23 result with revenue up 11% YoY, EBITDA up 32% YoY, and PAT up 39% YoY. Notably, North America revenue reached a record high, supported by growth in complex generics and cost optimization strategies. The report highlights Lupin’s solid financial numbers, with revenue, EBITDA, and net profit all showing significant year-on-year growth.
The analyst’s bullish sentiment is reinforced by Lupin’s strong momentum in its complex portfolio, with expectations of complex generics contributing over 50% of revenue in the coming years. This projection underscores the potential for accelerated growth and improved margins for Lupin Ltd. With a differentiated portfolio driving solid performance and a promising outlook for future growth, independent analysts on Smartkarma see continued momentum for Lupin in the market.
A look at Lupin Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Lupin Ltd, a company known for its diverse pharmaceutical offerings, shows a promising long-term outlook based on its Smartkarma Smart Scores. With a high Growth score of 5, Lupin Ltd is positioned for substantial development and expansion in the future. Additionally, the company’s strong Dividend and Resilience scores of 4 each indicate a stable financial standing and a commitment to rewarding its investors. This combination of growth potential and financial stability bodes well for Lupin Ltd‘s future prospects.
Lupin Ltd‘s Value score of 3 suggests that the company is reasonably priced in relation to its intrinsic value, offering investors a decent entry point. In terms of Momentum, Lupin Ltd scores a 3, implying a moderate level of market interest and activity surrounding the company. Overall, Lupin Ltd‘s positive Smart Scores, particularly in Growth, Dividend, and Resilience, paint a favorable picture for the company’s long-term performance and attractiveness to investors.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
